Page 93 - Aet News Today

The Centers for Medicare and Medicaid Services has announced two value-based care alternative payment models set to launch in July 2024, one focused on dementia and one on primary care.

Precision medicine for neurodegenerative conditions has the potential to radically change the way patients are treated and managed over time. As an industry, we must continue to expand our thinking and push the boundaries of science, technology, and data analytics to capture precision medicine opportunities in broader areas of unmet medical needs.

Pitango Venture Capital, one of the largest venture capital firms in Israel, announced the first closing of a new $175 million healthcare technology fund. With the new fund, the firm plans to build a portfolio of approximately 15 new companies over a period of three to four years.

Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.

By following these foundational data best practices, healthcare organizations will harness the power of their data to provide superior patient care while safeguarding patient privacy and compliance.

A webinar sponsored by AVIA Health and SeamlessMD will discuss the latest trends in remote monitoring and how to extend these benefits beyond chronic conditions all while using fewer staff resources.

Apprehension among practices and providers is understandable, given the complexity and variance of VBC contracts. However, instead of feeling overwhelmed and burdened by VBC, practices can slowly embrace these concepts by leveraging the many tools they already have in place or that exist in the healthcare ecosystem.

When violence in general—including gun violence—goes unchecked in any hospital setting, the physical and psychological impact can be severe, lasting and even devastating. Beyond injuries and tragic loss of life, the fallout from unchecked violence creates worker anxiety, loss of productivity and workdays, and significant legal and reputational losses.

Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.

Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.